Federal Judge Dismisses FTC’s Antitrust Claims Over Delay in Generic Drug’s Rollout
An Atlanta federal judge's dismissal of the Federal Trade Commission's antitrust claims against several pharmaceutical companies that delayed a generic drug's market rollout through a settlement is a setback for the agency's opposition to such deals. Pharmaceutical companies claim the ruling affirms that patent settlements are pro-competitive and pro-consumer. But the FTC's Richard Feinstein says the ruling "underscores the need for a legislative solution."
